Trustees’ Annual Report 2025
UK Acute Oncology Society (UKAOS)
Charity registration number: 1199351
Legal form: Charitable Incorporated Organisation (CIO) Reporting period: [insert start date] to [insert end date] Gross income: Less than £25,000
Principal office: UKAOS Secretariat, c/o Media1 Productions Ltd, Clarence Mill, Clarence Road, Bollington, Macclesfield SK10 5JZ
Reference and administrative details
Trustees who served during the reporting period:
-
Ernest Marshall Chair
-
Joanne Upton Trustee
-
Donna Munro Trustee
-
Philippa Jacqueline Jones Trustee
-
Dr Hilary Williams Trustee
-
Dr Caroline Wilson Trustee
Structure, governance and management
UKAOS is a Charitable Incorporated Organisation governed by its constitution dated 16 June 2022 and updated on 18 January 2025. The Board of Trustees is responsible for the charity’s strategic direction, financial stewardship, legal compliance and oversight of risk.
Trustee appointment, induction and organisation
Trustees are appointed in accordance with the constitution, having regard to the skills, experience and diversity of perspective required by the Board. New trustees receive appropriate induction on the charity’s purposes, governing document, trustee duties, finances and current priorities.
How the charity is managed
-
Board of Trustees: The governing body responsible for the overall strategic direction, financial oversight, and legal compliance of the charity.
-
Operational Steering Group: Oversight of Operational delivery of the work plan and strategy
1
-
Programme Management Group: Responsibility for cross cutting themes and governance policy development.
-
Sub-groups with defined scope and terms of reference.
Objectives and activities
Charitable purposes
-
For the public benefit to advance the education of all healthcare professionals involved in treating or supporting patients in the field of acute oncology
-
In furtherance of the object above, to promote research for the public benefit in all aspects of that subject and to publish the useful results
-
The relief of sickness and preservation of health, from cancer.
-
To assist in the treatment and care of persons suffering from cancer, or in need of rehabilitation, by the provision of education for healthcare professionals
-
To promote the wellbeing of people suffering from acute effects of cancer and/or anti-cancer treatment and support the development of acute oncology services
Public benefit
The trustees have had due regard to the Charity Commission’s guidance on public benefit when planning and delivering the charity’s work.
UKAOS advances education for healthcare professionals involved in acute oncology, promotes research and dissemination of useful findings, and supports improvements in the treatment, care and wellbeing of people affected by cancer and the acute effects of cancer treatment.
During the year, the charity delivered public benefit through:
-
Education: conferences, online learning and professional events designed to improve the quality and safety of urgent cancer care.
-
Service improvement: development and publication of practical pathways, reviews and guidance for acute oncology services.
-
Research, data and policy: collaboration with national partners to strengthen evidence, data quality and the voice of acute oncology in national cancer policy.
Achievements and performance
The charity’s principal achievements during the year are summarised under six strategic themes.
2
-
Publications and guidance. Published the first five-year UKAOS strategy; launched a four-nation review of 24/7 systemic anti-cancer therapy helplines; published initial Same Day Emergency Care pathways for unexpected pulmonary embolism, metastatic spinal cord compression and low-risk febrile neutropenia; and progressed reviews of malignancy of unknown origin services and acute oncology in emergency departments.
-
Education. Delivered the UKAOS annual conference and established the online Learning Hour programme, alongside contributions to national oncology and systemic anti-cancer therapy events.
-
Urgent cancer care data. Continued work to improve reporting through the Cancer Outcomes and Services Dataset and CancerStats2, and secured a national partnership with Macmillan Cancer Support and the National Disease Registration Service to investigate urgent-care use among people with lung cancer receiving systemic anti-cancer therapy.
-
Governance and policy. Completed a governance review, established an Operational Steering Group and continued to develop policies and procedures to support effective oversight.
-
Income generation. Explored fundraising opportunities to strengthen the charity’s education and service-improvement work.
-
National policy. Supported the inclusion of a commitment to develop acute and supportive oncology quality standards within national cancer policy.
Financial review
The charity’s gross income for the reporting period was less than £25,000. Full details of receipts, payments, assets and liabilities are set out in the annual accounts approved by the trustees.
Reserves: The charity did not have a formally approved reserves policy at the reporting date. The trustees will develop and approve an appropriate policy during 2026, taking account of planned commitments, financial risks and the need for operational continuity.
Going concern: Having reviewed available funds and anticipated commitments, the trustees consider that the charity has adequate resources to continue its activities for the foreseeable future, subject to confirmation when approving the accounts.
3
Debts and custodian funds: “The charity had no material debts and held no funds as custodian trustee at the year end.”]
Risk management and trustee
responsibilities
The trustees regularly consider the principal risks facing the charity and take proportionate steps to manage them. These include financial sustainability, governance capacity, data protection, reputation and delivery of activities through partners or volunteers.
The trustees are responsible for maintaining proper accounting records, safeguarding the charity’s assets, preparing annual accounts and a trustees’ annual report, and ensuring that the charity acts in accordance with its constitution and applicable law.
Serious incidents: No serious incidents requiring a report to the Charity Commission were identified
Plans for the next reporting period
-
Continue delivery of accessible education for acute oncology professionals.
-
Complete and disseminate further service reviews, pathways and guidance.
-
Strengthen partnerships supporting urgent cancer care data and research.
-
Embed the revised governance framework and complete the next phase of policy development.
-
Approve a proportionate reserves policy and pursue sustainable income opportunities.
Approval and declaration
This report was approved by the Board of Trustees on [insert date] and signed on its behalf by:
Ernest Marshall, Chair
4
Signature: _ ___ Date: __02/09/2026__
5
2025
| ⚖ CHARITY COMMISSION FOR ENGLAND AND WALES |
CharityName | CharityName | |
|---|---|---|---|
| UK Acute Oncology Society (UKAOS) | |||
| For the period from |
Period start date 1-Jan-25 |
Section A Receipts and payments
Unrestricted Restricted funds funds to the nearest £ to the nearest £
A1 Receipts
| A1 Receipts | ||
|---|---|---|
| Sponsorships and grants | 25,000 | |
| Sub total (Gross income for AR) |
25,000 | - |
| Funds received in error | 0 | |
| Sub total | 0 | - |
| Total receipts | 25,000 | |
| A3 Payments | ||
| Bank charges | 240 | |
| Website expenses | 1473 | |
| Secretariat | 6,708 | |
| Accountancy | 924 | |
| Repayment for funds received in error |
0 | |
| Sub total | 9,345 | - |
| Sub total | - | |
|---|---|---|
| Total payments | 9,345 | - |
| Net of receipts/(payments) | 15,655 | - |
| A5 Transfers between funds | 4,755 | |
| A6 Cash funds last year end | 20,410 | - |
Section B Statement of assets and liabilities at the end of the period
Categories Details B1 Cash funds Bank
| B2 Other monetary assets B3 Investment assets |
Details |
|---|---|
| Details | |
Details
B4
Assets retained for the charity's own use
Details
B5
Signed by one or two trustees on behalf of all the trustees
Liabilities
Signa
CCXX R2 accounts (SS)
No (if any) 1199351 Receipts and payments accounts Period end date To 31-Dec-25
| Endowment Total funds funds to the nearest £ to the nearest £ |
Endowment Total funds funds to the nearest £ to the nearest £ |
Last year to the nearest £ |
|
|---|---|---|---|
| 25,000 | 14,000 | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | 25,000 | 14,000 | |
| 0 | 4,800 | ||
| - | 0 | 4,800 | |
| 25,000 | 18,800 | ||
| 240 | 265 | ||
| 1473 | 848 | ||
| 6708 | 21,306 | ||
| 924 | 900 | ||
| 10,800 | |||
| - | 9,345 | 34,119 | |
| - |
| - | - | - |
|---|---|---|
| - | 9,345 | 34,119 |
| - | 15,655 | -15,319 |
| 4,755 | 20,074 | |
| - | 20,410 | 4,755 |
Unrestricted Restricted funds funds to nearest £ to nearest £ 20,410 Total cash funds 20,410 - (agree balances with receipts and payments account(s)) OK OK Unrestricted Restricted funds funds to nearest £ to nearest £
Fund to which
asset belongs Cost (optional)
Fund to which
asset belongs Cost (optional)
| Fund to which Amount due liability relates (optional) |
Fund to which Amount due liability relates (optional) |
Fund to which Amount due liability relates (optional) |
|---|---|---|
| ature Print Name |
||
| E MARSHALL | ||
2
CHARnY COMMISSION Recel For thg poriQ Sectlon A Recelpts and payments Al Roc rants AHJ un r•c•i 265 '4PheJsrt9 f X 695 ReP&Yrnet for luTrJ¥ recelved J4,119 A4 A6s•1 and In¥•m• AS 1 A6 Ca¥h C•sh lunds thi¥ •rnl Section B Statefnent of a55et5 and l i
-15,319
0
OK
Endowment funds to nearest £
----- Start of picture text -----
-
----- End of picture text -----
Endowment
funds
to nearest £
Current value
(optional)
Current value
(optional)
When due
(optional)
Date of approval 9/18/2026
9/18/2026
Socil IJKAOS monts accounls I tsand CC10a 01-J-2 31 tJ¢ 74 funds Total .oo• fi.QDU 265 90D )4.119 10.420 Y.119 bililies at the end of Ihe perlod fuivJ• I5 fvnaT5 4.755 Vnwèstskted turMI Retrl<ie
Fwnd Pnnt Trlame E laARSHALL 24110.202J ¥Jtlf43025
2025 Incom
Income and Expenditure Account UK Acute Oncol
Income from Donations
| Income from Donations | |
|---|---|
| Date | Category |
| 1/28/2025 | Income |
| 4/24/2025 | Income |
| 8/1/2025 | Income |
| 12/19/2025 | Income |
| 12/22/2025 | Income |
| Total Result |
Expenditure from Donations
| Expenditure from Donations | Expenditure from Donations | |
|---|---|---|
| cleaned narrative | Date | |
| Outward Faster Payment – Media 1productions | 12/16/2025 | |
| Account to Account Transfer – SAWIN & EDWARDS LLP | 11/6/2025 | |
| Outward Faster Payment – Frank Design Ltd | 11/6/2025 | |
| Online Banking Monthly Fee | 1/31/2025 | |
| 2/28/2025 | ||
| 3/28/2025 | ||
| 4/28/2025 | ||
| 5/28/2025 | ||
| 6/27/2025 | ||
| 7/28/2025 | ||
| 8/28/2025 | ||
| 9/26/2025 | ||
| 10/28/2025 | ||
| 11/28/2025 | ||
| 12/24/2025 | ||
| Total Result |
me and Expenditure Account
ogy Society (UKAOS)
| cleaned narrative | Sum of Mone |
|---|---|
| Inward Payment – GILEAD SCIENCES LTD(ref: 012/11.12.2024) | 4000 |
| BACS Payment Received – DAIICHI(0150000359) | 4000 |
| Inward Payment – CAREOLOGY HEALTH LIMITED | 500 |
| BACS Payment Received – BIOMERIEUX UK LTD(00072000318198) | 12500 |
| BACS Payment Received – ASTRAZENECA UK LIM(INV/106625779) | 4000 |
| 25000 |
| Category | Sum of Mone |
|---|---|
| Secretariate | 6708 |
| Audit Costs | 1473 |
| WebSite | 924 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| Bank Fees | 20 |
| 9345 |
| Opening Bank Balance (1/1/25) | 4755.4 | |
|---|---|---|
| Income | 25000 | |
| ey In (£) | Expenditure | 9345 |
| Closing Bank Balance | 20410.4 |
ey Out (£)
Account5tu*•m•nt ETRO BANK J1 JAN2D2 £4 Y554ts SortC4 rdb
Source: Ban
Date
1/31/2025 2/28/2025 3/28/2025 4/28/2025 5/28/2025 6/27/2025 7/28/2025 8/28/2025 9/26/2025 10/28/2025 11/28/2025 12/24/2025 1/28/2025 4/24/2025 8/1/2025 12/19/2025 12/22/2025 11/6/2025 11/6/2025 12/16/2025
nak Statements
Description Online Banking Monthly Fee [eu-prod.as...rosoft.com] Online Banking Monthly Fee [eu-prod.as...rosoft.com] Online Banking Monthly Fee [statement-...25-January | PDF] Online Banking Monthly Fee [statement-...5-February | PDF] Online Banking Monthly Fee [statement-2025-March | PDF] Online Banking Monthly Fee [statement-2025-April | PDF] Online Banking Monthly Fee [statement-2025-May | PDF] Online Banking Monthly Fee [statement-2025-June | PDF] Online Banking Monthly Fee [statement-2025-July | PDF] Online Banking Monthly Fee [statement-...025-August | PDF] Online Banking Monthly Fee [statement-...-September | PDF] Online Banking Monthly Fee [statement-...25-October | PDF] Inward Payment – GILEAD SCIENCES LTD (ref: 012/11.12.2024) [eu-prod.as...rosoft.com] BACS Payment Received – DAIICHI (0150000359) [statement-...5-February | PDF] Inward Payment – CAREOLOGY HEALTH LIMITED [statement-2025-June | PDF] BACS Payment Received – BIOMERIEUX UK LTD (00072000318198) [statement-...25-October | PDF] BACS Payment Received – ASTRAZENECA UK LIM (INV/106625779) [statement-...25-October | PDF] Account to Account Transfer – SAWIN & EDWARDS LLP (UKAOS) [statement-...-September | PDF] Outward Faster Payment – Frank Design Ltd [statement-...-September | PDF] Outward Faster Payment – Media 1 productions [statement-...25-October | PDF]
| Money In (£) | Money Out (£) | Balance After (£) | Category |
|---|---|---|---|
| 0 | 20 | 8735.4 | Bank Fees |
| 0 | 20 | 8715.4 | Bank Fees |
| 0 | 20 | 8695.4 | Bank Fees |
| 0 | 20 | 12675.4 | Bank Fees |
| 0 | 20 | 12655.4 | Bank Fees |
| 0 | 20 | 12635.4 | Bank Fees |
| 0 | 20 | 12615.4 | Bank Fees |
| 0 | 20 | 13095.4 | Bank Fees |
| 0 | 20 | 13075.4 | Bank Fees |
| 0 | 20 | 13055.4 | Bank Fees |
| 0 | 20 | 10638.4 | Bank Fees |
| 0 | 20 | 20410.4 | Bank Fees |
| 4000 | 0 | 8755.4 | Income |
| 4000 | 0 | 12695.4 | Income |
| 500 | 0 | 13115.4 | Income |
| 12500 | 0 | 16430.4 | Income |
| 4000 | 0 | 20430.4 | Income |
| 0 | 1473 | 10658.4 | Audit Costs |
| 0 | 924 | 12131.4 | WebSite |
| 0 | 6708 | 3930.4 | Secretariate |
cleaned narrative Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Inward Payment – GILEAD SCIENCES LTD (ref: 012/11.12.2024) BACS Payment Received – DAIICHI (0150000359) Inward Payment – CAREOLOGY HEALTH LIMITED BACS Payment Received – BIOMERIEUX UK LTD (00072000318198) BACS Payment Received – ASTRAZENECA UK LIM (INV/106625779) Account to Account Transfer – SAWIN & EDWARDS LLP (UKAOS) Outward Faster Payment – Frank Design Ltd Outward Faster Payment – Media 1 productions